A Second Attack, and a Drug Her Insurance Has Already Denied Once
Her insurer denied the targeted biologic once, on paperwork rather than clinical grounds, and the appeal has no timeline. She has had two attacks in six months and one has already cost her part of a visual field. What protects her while the appeal moves is the whole question.
Two attacks in six months, and the second is still visible in T.A.'s exam. She is 42, a paralegal. The first was a transverse myelitis episode that briefly took her ability to walk; the second, three weeks ago, was an optic neuritis that has left a partial visual field deficit which has not cleared. A high-titer AQP4-IgG confirms neuromyelitis optica spectrum disorder rather than MS — a distinction the group is treating as load-bearing, because where an MS relapse commonly recovers, an NMOSD attack frequently does not. Her own two attacks are already demonstrating the difference: the myelitis resolved, the optic neuritis has not, and three weeks is long enough that what remains is likely what she keeps.
Three targeted biologics reached approval between 2019 and 2020 on the strength of placebo-controlled trials — N-MOmentum for inebilizumab, PREVENT for eculizumab, SAkuraSky and SAkuraStar for satralizumab — with attack-rate reductions large enough to change how aggressively this disease gets treated the moment antibody status is known. Her neurologist requested inebilizumab. Her insurer denied it for undocumented step therapy, which is a paperwork objection rather than a clinical one, and the appeal is in progress with no committed decision date. So she sits today with a confirmed high-risk diagnosis, an unrecovered deficit, and nothing running, while the timeline is controlled by people neither she nor her care team can reach. What the group has to choose is not the best drug. It is what covers an interval of unknown length in a disease whose interval costs are measured in deficits that do not come back — and the two candidate bridges, azathioprine and off-label rituximab, differ less in whether they work than in how long each takes to start working.
After the second attack, with the appeal still pending
I'd start azathioprine today while the appeal continues. It has decades of real-world use in NMOSD with a genuine, if less dramatic, relapse-reduction effect — something protective started now is better than leaving her with nothing while we wait for an appeal of uncertain length. I'd send TPMT and NUDT15 genotyping with today's bloods rather than after, since a poor metabolizer would change the dose before the first tablet, not after the first count comes back low.
If she'd had a single mild attack rather than two, one of them already leaving residual deficit, I'd be less urgent about starting something today — it's specifically her own attack pattern that makes 'wait for the appeal' feel unacceptable to me.
I'd push the appeal hard and, if it doesn't resolve quickly, bridge with rituximab rather than azathioprine specifically. Look at what the targeted agents actually did against placebo: N-MOmentum (Cree et al., 2019) for inebilizumab, PREVENT (Pittock et al., 2019) for eculizumab, the SAkuraSky and SAkuraStar trials for satralizumab — all three read out between 2019 and 2020 with attack-risk reductions large enough to change how this disease gets treated the moment it's confirmed. That's the standard her appeal is fighting for. Meanwhile NMOSD attacks leave permanent deficit far more often than MS relapses do, and azathioprine takes months to reach a real immunosuppressive effect.
I'm not saying azathioprine is wrong in principle — I'm saying its slow onset specifically doesn't match how fast this disease has already moved in her case twice. A faster-acting bridge matters more here than it would in a patient whose disease had been quieter.
I don't think either of you has actually compared the thing this decision hinges on: how quickly azathioprine versus rituximab each reach a meaningful protective effect in practice, not just which one has the better general reputation for speed. That specific comparison, not drug-class habit, should decide the bridge.
You're both reasoning from real, relevant evidence, and I'm genuinely not certain which bridge wins once the actual onset-timeline comparison is made — I just don't think we should pick one over the other without making that comparison explicit first, especially given how much is riding on getting the bridge right for her specifically.
Agreed: rituximab started this week as the bridge, with the inebilizumab appeal pursued aggressively in parallel rather than waited on passively. Her care team documented the specific clinical urgency — two attacks in six months, one with confirmed residual deficit — directly in the appeal letter, since the original denial cited a documentation gap rather than a clinical judgment against the drug.
Not agreed: whether rituximab should simply become the long-term plan if the appeal is ultimately denied, or whether the group would keep appealing indefinitely given inebilizumab's stronger trial data. That question was set aside as premature — the group agreed to revisit it only if the appeal is actually denied, rather than pre-deciding a contingency that may not be needed.